-I mprovement of mammography techniques allowed the detection of breast cancer at an onsymptomatic stage. Many cases of DCIS appeared to manifest with microcalcifications on the mammogram. The introduction of mammographic screening of asymptomatic women resulted thus in amarkedly increased detection of DCIS. -B reast-conserving therapy (BCT) proved to be a safe alternative compared with mastectomy in patients with operable invasive breast cancer. Therefore the question rose whether the same treatment could be applied for patients with DCIS.
Since the early 1990s, population-based mammographic screening has been introduced in several western countries (15) , with the aim of detecting breast cancer at an earlier stage, and so to reduce breast cancer mortality (16) (17) (18) (19) (20) (21) . Currently, 13 countries have national or both national and regional funding of programmes (15) . As ar esult of this screening, there has been an enormous increase in the detection of patients with DCIS. About 15-20 %o fa ll detected breast cancers in screeningprogrammesare DCIS.Overall,the ageadjusted incidence of DCIS has increased five to tenfold in the past 20 years, with the largest increase after the start of the screening programmes (21) (22) (23) (24) . In recent years, European countries report aDCIS inci-
INTRODUCTION
Until the 1980s, DCIS was ar are disease. The lesion accounted for 2-3 %o fa ll symptomatic breast cancers, and was diagnosed because it presented with a palpable mass, nipple discharge, or Paget's disease of the nipple. These symptomatic DCIS were usually ill-defined, extensive lesions, spreading through a large part of as egment. At that time, mastectomy wast he standard treatmentf or allo perableb reast cancers. With this treatment, av irtually 100 %c ure rate could be obtained for DCIS. Missed invasive foci due to inadequate sampling at the time of diagnosis were considered the origin of the incidentally observed distant metastases after mastectomy for DCIS (1-3 %) (1-7).
Although DCIS is the precursor of most if not all invasive breast cancers, probably not all DCIS will progress into invasive carcinoma. Little is known about the natural history of DCIS, if left untreated. Autopsy series showed DCIS in the breast with afrequency ranging from 6t o1 8%in women who died of causes unrelated to breast cancer (8-10). This suggests that anumber of DCIS cases never become clinically-apparentinvasivetumours.The naturalcourse of the disease has been evaluated in afew studies in cases picked up by review of the histology of breast biopsies for lesions that were originally interpreted as benign. These studies found small numbers of women with misdiagnosed, and therefore untreated DCIS, and report rates of subsequent invasive breast cancer from 9of80cases (11) (11.3 %), to 9of28(12) (32 % ) and 8of15cases (13) (53 % ) after long followup periods( 18-30y ears). DCIS is ah eterogeneous dence of 6.2 to 9.9 per 100,000 women per year (22) (23) (24) . In the United States guidelines differ and an ational policy does not exist. Individual screening usually starts here for women from 40 years of age, resulting in as lightly higher incidence of 13.8 to 15.8 per 100,000 women (25) (26) .
This paper describes the optimal diagnostic process in patients, suspected to have DCIS, and the current knowledge to provide patients the best information to make choices for treatment.
DIAGNOSIS
DCIS is in the large majority of patients diagnosed as clinical occult lesion by screening mammography. In the series of 910 unselected patients, diagnosed with DCIS in the period of 1986-1996 in 5large cancer centres participating in the EORTC-10853 DCIS trial, 63 %w as diagnosed by screening mammography. In the EORTC-10853 trial itself, from the 1010 entered (thus selected patients for breast conservation), 722 (71 %) were mammography detected (27) . Microcalcifications are the most prominent mammographical feature of DCIS. In case of microcalcifications, radiologists should report on their morphology, arrangement and extent, and determine al evel of suspicion. High quality images, including craniocaudal and lateral views, and magnification views, are part of routine work-up. Ultrasound may be helpful to exclude am ass in the area of microcalcifications, which may suggest invasive cancer. Currently, it is considered standard of care to establish apreoperative diagnosis by stereotactic image guided core-biopsies in case of suspicious clinical occult lesions (microcalcifications) (28) (29) . Usually, at least 5 passes of a14gauge needle, or vacuum assisted needle biopsies are taken. Specimen radiographs are made to establish representativity of the biopsies in case of microcalcifications. With these biopsy techniques, at least 90 %o fc linical occult DCIS can be diagnosed preoperatively (30) (31) .
Why is this important? Once ar eliable preoperative diagnosis is obtained, definite treatment aimed at complete excision can be carried out. The availability of the diagnosis of an occult -in situ-cancer showed to be the most important factor related to completeness of the first therapeutic excision (29, 32) , the other factors being size of the lesion and the experience of the surgeon (32) .
To guide the surgeon, localisation of the lesion is mandatory. Placing ag uidewire by stereotactics or ultrasound is the most frequently used technique. To facilitate the surgeon, the tip of the wire should be within 1cmofthe dominant lesion.Incaseofalarge area of microcalcifications, multiple wires may be helpful to define the extent of alesion.
Without preoperative diagnosis and complete mammographic imaging, including magnifications views, and agood localisation procedure with apostlocalisation mammogram, asurgeon should not embark on an excision aiming at the tumour free margins as advised for breast conservation treatment of DCIS.
TREATMENT
If one considers breast conservation for DCIS, one should try to estimate as well as possible the risk for relapse. The review of risk factors for relapse within the EORTC-10853 DCIS trial revealed the following factors associated with an increased risk of recurrencei nam ultivariatea nalyses: younga ge (< 40 years, HR 2.14, P=0.02), symptomatic detection of DCIS (HR 1.80, P=0.008), growth-pattern, (solid and cribriform) (HR 2.67 and 2.69, respectively P=0.0012), involved margins (HR 2.07, P=0.0008), and treatment by local excision alone without radiotherapy(HR 1.74, P=0.009). The risk of recurrence was not related to the histological type of DCIS (P =0.56). However, the risk of distant metastasis was significantly higher in poorly differentiated DCIS compared with well differentiated DCIS (HR 6.65, P=0.008) (33) . Table 1g ives the overview of these figures.
It should be kept in mind that these figures are seen after an intended complete excision of DCIS. The risk factors should be used to inform the patient as such that the estimated risk of invasive breast relapse is less than 10 %after 10 years (34) .
Assessment of risk factors requires amultidisciplinary work-up. This includes radiologic evaluation of the adequacy of surgery by comparison of preoperative mammography, specimen X-ray and postoperative mammography. Assessment of extent of the lesion and margin status further demands the diagnostic work-up by the pathologist, according to established guidelines (34, 35) .
The aim of surgical treatment of DCIS is to achieve tumour free margins (36) . There is no consensus about this minimum tumour free width. When considering breast conservation, the surgeon should aim at amargin of at least 1cmaround the area of calcifications; the microscopic extent of DCIS usually exceed the mammographic area of calcifications. If margins are involved, ar e-excision (guided by postoperative mammography and, if necessary, again a guidewire localisation) should be attempted. When ar e-excision will result in poor cosmesis, am astectomy (with or without immediate reconstruction) should be considered.
If on basis of mammographical findings, the DCIS is considered to be too large for breast conservation (usually exceeding a3 -4 cm area of microcalcifications) immediate mastectomy, with or without reconstruction, should be discussed.
Two randomised trials, the NSABP B-17 and the EORTC 10853 trials, have shown that radiotherapy to the breast (50 Gy) after complete excision, reduces breast relapse rates by 40 %after amedian follow up of about 5years, irrespective the histological features of the DCIS (27, 39) . Therefore, the possibility of radiotherapy should always be discussed with the patient who desires to conserve ab reast after complete excision of DCIS. However, there are still debates whether in every situation adjuvant radiotherapy is warranted. There are instances were the risk of invasive local relapse, which may lead to dissemination, is extremely low (36) . These are those patients with small (< 2cm) foci of DCIS of low grade, and DCIS excised with histologically confirmed margins of more than 10 mm. In these situations, the adjuvant value of radiotherapy seems limited.
AXILLARY STAGING
In DCIS, diagnosed by meticulous histologic sampling, the risk of missed invasive foci is limited. Lymphatic staging i.e. axillary clearance or sentinel node biopsy is not indicated in this situation. The panel of the Philadelphia Consensus Conference, on the role of sentinel lymph node biopsy (37), had the following considerations on sentinel node biopsy in DCIS. For its low morbidity, sentinel lymph node biopsy (SLNB) has led to its use in patients with DCIS based upon reported observations of occasional axillary node metastasis in these patients. In patients with mammographically detected DCIS, or with the diagnosis of DCIS made as an incidental finding, SNLB is not indicated. When DCIS is detected as ap alpable mass by large areas of calcifications and the treatment is mastectomy, SLNB may be useful. The addition of SNLB to the mastectomy obviates the need for subsequent axillary dissection which is at echnical challenging procedure, particularly if immediate reconstruction has been carried out, if invasive carcinoma is found in the mastectomy specimen.
TAMOXIFEN IN DCIS
Two trials have been conducted evaluating the effect of adjuvant Tamoxifen in reducing breast relapse after breast conserving treatment in DCIS: the NSABP-B24 trial and the U.K. DCIS trial. Published data are available from the B-24 trial (40) . In this study, 1804 patients were randomly assigned to lumpectomy plus radiation therapy (50 GY) and placebo (n =902) or lumpectomy plus radiotherapy and Tamoxifen (20 mg daily for 5y ears, n=902). Involved margins after lumpectomy (16 %i nb oth groups) were allowed. After amedian follow-up of 74 months, women in the Tamoxifen group had significantly fewer breast cancer events (and particularly local recurrences) at 5y ears, compared with those in the placebo group (8.2 %v ersus 13 %, P=0.009). No width of margin clearance on histology was required in this trial and this is likely to explain the high recurrence rate in both arms. This trial has raised an umber of questions of interpretation. The trial results are from ar elatively short-term follow-up. Over 80 %o fp atients had DCIS lesions less than 1cm. As in population-based series screened detected DCIS are on average or larger size, patients for this study appear to have been selected for smaller lesions. The effect of Tamoxifen is particularly seen in patients with known risk factors for breast relapse: younger age, positive margins, the presence of comedo necrosis and tumours detected by clinical examination being usually the larger lesions. This raises the question of the magnitude of the absolute effect of Tamoxifen in patients with alow risk of relapse.
At am edian of 4y ears, the 902 patients treated with Tamoxifen had 29 fewer invasive breast cancers and 17 fewer in situ carcinomas, but 8e xtra thrombo-embolicevents and 5extra endometrium cancers. It is clear that Tamoxifen must not be used to compensate for inadequate local treatment. Therefore, there is no role for Tamoxifen following wide local excision plus radiotherapy in patients who have clear When the patient desires breast conserving surgery, but clear margins can not be achieved, Tamoxifen may be prescribed for 5y ears in case of ER positive tumours. However, these patients must be made aware that the risk of recurrence is higher than that achieved by mastectomy, and about the side effects of Tamoxifen.
SUMMARY AND MANAGEMENT ADVISES
Table2summarisesthe clinical relevant issues in the management of patients with DCIS. DCIS is ad isease which should be managed in amultidisciplinary team. The advice mentioned in the table are to agreat extend explanatory to the requirement that every patient should be discussed pre-and postoperatively within this team. DO:
-C omplete work-up imaging: mammography, magnification views, and if adensity is suspected, including ultrasound. -T ry to achieve in >90%of the patients with DCIS a preoperative diagnosis with stereotactic guided core-biopsies. If the lesion is visible with ultrasound, an ultrasound guided core-biopsy is agood option. -C heck the core-biopsies on the presence of microcalcifications. -A im at acomplete excision of the DCIS with amargin of 1cm. -A sk the radiologist to place aguide wire before excision with the tip of the wire within 1cmofthe lesion. -A im at one excision specimen in aso-called anatomical sector resection. Checking for completeness of multiple specimens by the pathologist is difficult. -M ark the specimen before sending to the pathologist. -I fmicro-calcifications are extended over more than 3-4cmon mammography, acosmetically acceptable resection of the DCIS will hardly ever be complete. -H ave acomplete histological work-up: inking of margins, slicing of the specimen, have aradiogram of the sliced specimen, take multiple blocks and slides. -O nly after acomplete excision of DCIS, local relapse rates are within acceptable limits. -H owever, there is no consensus as to what safe complete margins are. Pathologists throughout the world cannot reach consensus on this. Aworkable aim is over two mm microscopically free margin. -T here is no reason to excise entry-sites of fine needle aspiration or core-biopsy in local excision. -I fasimple mastectomy is indicated, always offer the possibility of direct reconstruction. -A direct reconstruction has anumber of advantages compared to delayed reconstruction. -I ncase of amore extensive DCIS and the preoperative diagnosis with core biopsy cannot exclude invasive cancer, a sentinel node procedure can be considered. -I nbreast conservation, adjuvant radiotherapy is astandard advice. -T he role of adjuvant Tamoxifen in locally adequate treated DCIS is unclear.
DO NOT:
-R emove the lesion without knowing what it is (always try to achieve preoperative diagnosis!). -R emove the lesion without having available the mammography on the operation-room. -R emove the lesion without alocalisation procedure.
-R emove the lesion in parts which are not recognisable and anatomically to be reconstructed after excision. -M iss the invasive part.
-P erform an axillary clearance. -P erform asentinel node procedure if you are certain that it is aDCIS. -F orget to refer the patient to the radiotherapist. -F orget to make amammogram after excision of the microcalcifications and before radiotherapy. -F orget to explain to the patient that DCIS is basically a curable lesion, the risk of distant metastases is nil and there is along life expectancy: this means that the breast has along risk to develop arecurrence.
